Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 26th, particularly in innovative drugs and vaccine concepts, with several companies seeing significant stock price increases [1] Industry Summary - Recent advancements in the small nucleic acid drug field have garnered significant attention from both the industry and investors, marking a transition from concept validation to the brink of industrial rise [1] - Since 2025, breakthroughs in delivery technology are expected to expand indications from the liver to cardiovascular and CNS areas, coupled with the commercialization of major products and substantial mergers by multinational pharmaceutical giants, indicating a golden development period driven by "technological breakthroughs + commercial realization" [1] - According to Everbright Securities, domestic pharmaceutical companies are accelerating their R&D progress, with many entering clinical research phases since 2025. The focus should be on leading innovative drug companies with advanced technology platforms and differentiated pipelines, as well as innovative industry chain companies likely to benefit from the overall industry upturn [1] - The investment approach in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion strategies, which are assigning higher premiums to clinical value [1] - From the perspective of clinical value, the innovative drug industry chain and innovative medical devices are viewed positively [1]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a strong rally, driven by increased demand for flu-related medications and the growth of innovative domestic drugs in international markets [1] Group 1: Market Performance - The Hong Kong pharmaceutical sector saw significant gains, with companies like InnoCare Pharma, Rongchang Bio, CSPC Pharmaceutical, and 3SBio all rising over 6% [1] - The Hong Kong Innovative Drug ETF (159567) increased by over 3% as of 9:51 AM, with a trading volume exceeding 600 million yuan [1] - As of November 25, the ETF has recorded a net inflow of 903 million yuan for the month [1] Group 2: Demand Trends - There is a notable increase in demand for flu medications on the Alibaba Health platform, with a more than 500% week-on-week growth in the number of buyers for antiviral flu drugs during the recent two weeks (November 10-23) [1] Group 3: Industry Outlook - Institutions believe that more domestic innovative drugs are achieving value upgrades through international expansion, with overseas licensing transaction amounts reaching new highs, providing new momentum for sector growth [1] - The long-term positive trend in the innovative drug industry is expected to continue, extending from performance realization to business development in international markets [1]

Core Insights - A prominent private equity manager recently issued a rare apology due to significant losses, with most funds experiencing a net value decline of 7%, representing a 20% drawdown from peak levels, and underperforming various indices [1][3] - The losses were attributed to heavy investments in innovative pharmaceuticals, hardware leading companies with declines exceeding 37%, and stablecoin stocks in the U.S. [1] - The situation reflects a typical "betting on sectors" strategy, which can lead to substantial gains if successful, but also carries inherent risks [1] Investment Strategy Insights - The apology from the private equity manager is seen as insufficient, as the losses ultimately fall on clients, highlighting the need for a swift adjustment in investment strategies to prioritize client interests [2] - Losses in the current favorable market environment are considered unusual, especially when the broader market indices, such as the CSI 300, have yielded a 14% return year-to-date [3] - The situation serves as a cautionary tale for individual investors, emphasizing the importance of a balanced investment approach rather than chasing high-risk opportunities [5] Recommendations for Individual Investors - It is advised that individual investors simplify their investment strategies, focusing on manageable investments rather than high-risk sector bets [5] - A balanced investment approach, aiming for returns slightly above index performance, is recommended, as evidenced by the strong performance of balanced public quantitative funds this year [5] - The preference for investing in well-managed public funds is highlighted, as they tend to offer more professional management compared to individual stock picking [5]

Group 1 - The Hong Kong stock market has shown strong performance in 2023, with the Hang Seng Index and Hang Seng Tech Index rising by 29.09% and 25.60% respectively as of November 25 [1] - The performance in 2025 is expected to be driven by liquidity and sentiment, characterized by a chase for "scarce return assets" due to "excess liquidity" [2][6] - Despite the market's strong performance, overall earnings of listed companies in Hong Kong are slightly below initial expectations for 2025, with sectors like biopharmaceuticals and technology hardware showing resilience, while e-commerce and real estate face pressure [3] Group 2 - The liquidity environment is expected to remain accommodative in the first half of 2026, with potential interest rate cuts by the Federal Reserve, although long-term rates may stay high [3][4] - Southbound capital is projected to continue flowing into the Hong Kong market, with an estimated inflow of 600 billion HKD from public funds and insurance capital, alongside a potential 500 billion HKD from individual investors [3][4] - Investment preferences are shifting, with Southbound funds diversifying from high-dividend stocks to growth sectors, focusing on AI technology and structural recovery opportunities [4] Group 3 - The core macro theme for 2026 is expected to revolve around "excess liquidity chasing scarce return assets," with limited expansion of "scarce assets" [6] - Investment opportunities are identified in three main areas: AI-driven industry trends, cyclical recovery in production capacity, and export and commodity sectors related to global uncertainties [6] - Investors are advised to maintain flexibility in their strategies, balancing between chasing structural growth and managing market volatility [6]

Core Insights - Since 2025, China's innovative pharmaceuticals have experienced a "simultaneous leap in scale and quality" driven by policy benefits and industry accumulation, with total outbound licensing exceeding $90 billion by the end of October, nearly doubling from $51.9 billion in 2024 [1] - The third quarter saw a significant increase in the "value" of outbound transactions, with notable collaborations such as the global strategic partnership between Hengrui Medicine and GSK, involving 12 innovative drugs and potential milestone payments of up to $12 billion [2][3] - The overall trend indicates three structural changes in China's innovative pharmaceuticals' outbound efforts: an increase in high-value transactions, diversification of technology areas, and enhanced contributions from emerging markets [4] Group 1: Market Performance - The total amount of outbound licensing has surpassed $90 billion, indicating a robust growth trajectory [1] - Hengrui Medicine's collaboration with GSK includes a $500 million upfront payment and potential milestone payments of $12 billion, showcasing the shift from traditional licensing to collaborative development [2] - BeiGene's global sales of its core product, Zebrutinib, reached 7.423 billion yuan, marking a 51% year-on-year increase, with the U.S. market contributing significantly [2][3] Group 2: Structural Changes - High-value transactions are becoming mainstream, with large upfront payments and high-potential milestone clauses [4] - Collaborations are diversifying beyond oncology to include areas like autoimmune diseases and rare diseases [4] - There is a rising trend of local partnerships in countries along the Belt and Road Initiative, which helps reduce costs and expedite market entry [4] Group 3: Challenges and Opportunities - Despite the impressive growth, there are underlying issues such as insufficient internal capabilities and a lack of robust ecological support, which hinder the industry's collective advancement [5][6] - The phenomenon of "selling seedlings" reflects the financial pressures faced by many companies, leading to a reliance on licensing rather than developing their own capabilities [6][7] - The report suggests that targeting Belt and Road countries could provide a strategic opportunity for mid-sized and smaller companies to meet local demand for affordable innovative drugs [8][9] Group 4: Future Directions - The report emphasizes that Chinese pharmaceutical companies should not only focus on drug exports but also on promoting a comprehensive "going out" strategy that includes technology and supply chain integration [9] - The transition from merely "product output" to "technology output" represents a significant evolution in China's pharmaceutical industry, enhancing its global competitiveness [9]

来源：新浪基金∞工作室 港股创新药ETF（159567）现任基金经理为马君。马君自2024年1月3日管理（或拟管理）该基金，任职 期内收益68.04%。 最新定期报告显示，港股创新药ETF（159567）重仓股包括百济神州、康方生物、信达生物、中国生物 制药、中国生物制药、石药集团、三生制药、翰森制药、科伦博泰生物-B、再鼎医药，持仓占比如下。 股票代码股票名称持仓占比持仓股数（股）持仓市值（元）06160百济神州10.62%436.35万8.17亿09926 康方生物10.55%630.20万8.12亿01801信达生物10.21%893.55万7.86亿01177中国生物制药9.62%9966.80万 7.41亿08027中国生物制药9.62%9966.80万7.41亿01093石药集团7.56%6809.40万5.83亿01530三生制药 7.25%2038.75万5.58亿03692翰森制药5.39%1260.00万4.15亿06990科伦博泰生物-B3.48%57.08万2.68亿 09688再鼎医药2.73%862.34万2.10亿 港股创新药ETF（159567）成立于2024年1月3日，基金全 ...

Market Performance - The Shanghai Composite Index rose by 0.87% to 3870.02 points, the Shenzhen Component Index increased by 1.53% to 12777.31 points, and the ChiNext Index gained 1.77% to 2980.93 points, while the Sci-Tech Innovation 50 Index rose by 0.43% to 1302.17 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 18121.47 billion [1] Sector Movements - AI application concepts saw a resurgence, with stocks like Rongji Software hitting the daily limit [1] - The cross-strait concept continued to perform strongly, with multiple stocks such as China Wuyi also reaching the daily limit [1] - The flu-related concept showed active performance, with stocks like Hainan Haiyao hitting the daily limit [1] Stock Performance - A total of 148 stocks rose by more than 7%, while 150 stocks increased by 5-7%. Additionally, 452 stocks rose by 3-5%, and 3550 stocks saw gains of 0-3% [5] - On the downside, 925 stocks fell by 0-3%, with 48 stocks declining by 3-5% and 10 stocks dropping by 5-7% [5] - The total number of stocks that rose was 4300, while 893 stocks experienced declines [5] Notable Stocks - Rongji Software achieved a 7-day streak with 6 limit-ups, driven by factors such as AI and data elements [6] - Hainan Haiyao and other pharmaceutical companies saw significant increases due to rising demand for flu medications, with sales of Oseltamivir increasing by 237% and Baloxavir Marboxil by 180% in the past week [8]

Group 1: Mobile Games - The article discusses the growth and potential of the mobile gaming industry, highlighting its increasing popularity and revenue generation in recent years [1]. Group 2: ETF Grid Strategy - The ETF grid strategy focuses on several key ETFs, including the Hang Seng Innovative Drug ETF (520500.SH), which benefits from unprecedented domestic policy support for innovative drug development, such as the establishment of a "dual directory" multi-level payment system [3][4]. - The innovative drug pipeline in China has reached 7,041 projects, accounting for 29.5% of the global total, with a year-on-year growth of 15.1%, significantly outpacing the global average [4]. - The military ETF (512560.SH) is expected to benefit from a historical high defense budget of 1.81 trillion yuan in 2025, which represents a 7.2% increase, although it remains below 1.3% of GDP [7]. - The liquor ETF (512690.SH) has shown wide fluctuations in 2025, with an average daily amplitude of 1.77%, providing opportunities for frequent trading and profit capture [11]. - The Sci-Tech Chip Design ETF (588780.SH) focuses on the chip design sector, which is crucial for China's strategy to achieve technological self-reliance amid global competition [14].

Market Overview - The Hong Kong stock market showed a significant recovery on November 24, with all three major indices ending a streak of declines[9] - Large tech stocks performed strongly, with Kuaishou rising over 7%, and NetEase and Bilibili increasing over 5%[9] - The Hang Seng Tech Index closed at 5,546, up 2.78% for the day and 24.11% year-to-date[3] Sector Performance - Innovative pharmaceuticals and outsourcing concepts saw notable gains, with companies like Innovent Biologics rising over 6%[9] - Military stocks also performed well, with China Shipbuilding Defense up over 13%[9] - Oil stocks were weak, with China National Offshore Oil Corporation and China Oilfield Services both declining over 1%[9] U.S. Market Insights - On the same day, U.S. markets saw all three major indices close higher, driven by increased bets on a Federal Reserve rate cut[9] - The "Magnificent Seven" tech stocks, including Google and Nvidia, all rose, with Google gaining over 6%[9] - The S&P 500 index is projected to achieve double-digit annual growth according to HSBC strategists[14] Economic Indicators - The Federal Reserve is expected to cut rates in December, with market predictions showing a 70% probability[14] - The U.S. economy's third-quarter GDP report has been delayed due to a government shutdown, affecting economic analysis[14] Investment Trends - The Nasdaq Golden Dragon China Index rose by 2.82%, indicating a positive trend for Chinese concept stocks[13] - Significant inflows into semiconductor stocks were noted, with companies like Broadcom surging 11%[13]

Group 1 - The overall market is expected to enter a sentiment recovery phase as various risk factors approach resolution, with a rebalancing of industry allocations anticipated [1] - The Federal Reserve's dovish stance and the potential for interest rate cuts in December may improve global liquidity expectations [1][2] - Current adjustments in A-share popular sectors and broad indices are nearing historical average levels for emotional corrections, indicating potential short-term reversal signals [1] Group 2 - Emerging technology is expected to remain a key investment theme, with attention also on undervalued consumer stocks and brokerage firms [2] - The improvement in global industrial competitiveness is opening new growth opportunities for Chinese companies, particularly in sectors like internet, semiconductors, media, power equipment, and innovative pharmaceuticals [2] - The financial sector is seen as a crucial mechanism for stabilizing the market, with potential benefits from surging asset management demand and active market trading, focusing on brokerage, insurance, and banking [2]